Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06740526 · ClinicalTrials.gov registry record · Phase 2
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
A Phase 2 study of IgA Nephropathy, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 5
- Study locations
NCT06740526 is a Phase 2 study of IgA Nephropathy that is actively recruiting participants, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 25 participants, below the 165-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (85% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06740526, a Phase 2 study of IgA Nephropathy, is actively recruiting participants, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.
Conditions Studied
Interventions
- DRUG Sibeprenlimab
Study Locations (5)
Colorado
- Clinical Research Site 330 - Denver
Massachusetts
- Clinical Research Site 369 - Boston
South Dakota
- Clinical Research Site 374 - Dakota Dunes
Texas
- Clinical Research Site 324 - Houston
Ontario
- Clinical Research Site 305 - Scarborough Village
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2029-04-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06740526
The ClinicalTrials.gov registry entry for NCT06740526 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (85% lower). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with IgA Nephropathy appearing as the primary indexed condition, and to 1 intervention - of which Sibeprenlimab is the first listed.
NCT06740526 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Massachusetts, South Dakota.
Frequently Asked Questions
What is clinical trial NCT06740526 about?
NCT06740526 is a clinical study titled "Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue". This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.
What is the current status of trial NCT06740526?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-11-19. Estimated completion is 2029-04-17.
What conditions does trial NCT06740526 study?
This clinical trial studies the following conditions: IgA Nephropathy.
What interventions are being tested in trial NCT06740526?
The interventions under investigation include: Sibeprenlimab (DRUG).
Who is sponsoring clinical trial NCT06740526?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06740526 being conducted?
This trial has 5 study locations across Colorado, Massachusetts, South Dakota, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgA Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
COMPLETED · Phase 2
-
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
COMPLETED · Phase 2
-
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
COMPLETED · Phase 2
-
Study of BHV-1400 in IgA Nephropathy
RECRUITING · Phase 1
-
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.